DRUG — Bright Minds Biosciences Income Statement
0.000.00%
Last trade - 00:00- CA$319.44m
- CA$261.73m
- 29
- 33
- 72
- 41
Annual income statement for Bright Minds Biosciences, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.48 | 8.8 | 15 | 7.37 | 2.81 |
| Operating Profit | -0.48 | -8.8 | -15 | -7.37 | -2.81 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.48 | -8.65 | -15 | -7.37 | -2.8 |
| Net Income After Taxes | -0.48 | -8.65 | -15 | -7.37 | -2.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.48 | -8.65 | -15 | -7.37 | -2.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.48 | -8.65 | -15 | -7.37 | -2.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.375 | -4.82 | -6.06 | -1.98 | -0.65 |
| Dividends per Share |